wolfy casino no deposit bonus codes 2023
The unfolding drama has paralyzed the government and raised concerns about the stability of the country's leadership. The implications of the arrests on the political landscape and the upcoming elections are yet to be fully realized, but one thing is clear – South Korea is facing a reckoning with its past and present that will have far-reaching consequences.The implications of the criticisms leveled against Evergrande extend beyond the company itself. The real estate industry in China, already facing challenges due to increasing regulatory scrutiny and policy changes, is now further rocked by the scandal involving Evergrande. Investors are growing increasingly cautious, and industry observers are closely monitoring the situation for potential ripple effects.
The highly anticipated sequel to the blockbuster animated film "Ne Zha" has finally set its release date on Chinese New Year's Day, adding to the excitement of the upcoming Spring Festival season. Titled "Ne Zha 2: The Demon Child Returns", the film is expected to once again captivate audiences with its unique blend of mythology, action, and humor.
Parade aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Slippers are the unsung heroes of the winter months. When measly socks don’t do the trick against cold hardwood floors, slippers always save the day with blissful warmth and plush comfort. It’s almost like having your feet swaddled by a fuzzy fur throw blanket . But, trendy slipper styles on the market can run you a pretty penny. Walmart’s Hometop Cozy Memory Foam Loafer Slippers are just $17 right now, and they just so happen to look like a popular style from Bombas that cost $85. Although slippers are a well-worthy daily luxury, you don’t have to pay high prices for a “toasty warm” pair to last you through the season. Hometop Cozy Memory Foam Loafer Slippers, $17 (was $19) at Walmart Courtesy of Walmart Hometop’s slippers are already a bargain at $19, but you can snag them today at an even better $2 price drop. They’re available in women’s sizes from 5 to 12 and offer a wider color selection with eight chic options, including a snowy white, wine red, soft pink, and classic black. The style features unique polar fleece insoles and comfy memory foam EVA footbeds, which not only mold to the shape of your feet with regular wear, but also provide soft arch support for those who deal with foot pain. Underfoot, the style has a non-slip rubber sole for stability on slick surfaces that’s durable enough to hold up outdoors. No need to swap shoes when you’re grabbing the mail or walking your pooch! The snug loafer silhouette makes these slippers a lot more functional too. It’ll keep your entire foot nice and warm while reducing the risk of your foot slipping out. Plus, “[the] toe area is slightly tipped up to help prevent tripping,” said one shopper, who deems them “superior quality.” Over 902 Walmart shoppers are singing the praises of these cozy steppers, saying they “Feel like you’re walking on clouds,” and are “so good for the price.” They’re a fraction of the cost of Bombas’ Sunday Slippers with nearly identical aesthetics and functionality, so we recommend saving your cash for your Black Friday shopping spree. Bombas Sunday Slippers, $85 at Bombas Courtesy of Bombas You might as well stock up on a few pairs for holiday gifting while sizes are in stock, too — considering you can buy five for the price of one Bombas pair. We’re willing to bet your loved one will slip these puppies on as they’re unwrapped on Christmas morning.At the ITTF World Championships, the Chinese team swept multiple gold medals in both the men's and women's events, demonstrating their outstanding individual skills and collective dominance. Players such as Ma Long, Fan Zhendong, and Chen Meng showcased their exceptional talent and composure under pressure, outclassing their opponents with their lightning-fast reflexes, precise placement, and strategic play.
China Life Insurance, one of the leading insurance companies in China, has recently released its financial report for the first 11 months of the year. According to the report, the company has achieved an accumulated original insurance premium income of approximately 644.3 billion yuan during this period, representing a year-on-year growth of 4.8%. This significant increase in premium income demonstrates the company's resilience and ability to adapt to the challenging economic environment.
Ross Barkley’s 85th-minute goal gave them victory in Germany after goals from John McGinn and Jhon Duran early in each half were cancelled out by Lois Openda and Christoph Baumgartner. That sent them up to third in the new league phase of the competition ahead of Wednesday’s games and with matches against Monaco and Celtic to come, Villa have an excellent chance of finishing in the top eight. Job done... in the end 😅 #RBLAVL #UCL pic.twitter.com/PRD1Hi1Q3A — Aston Villa (@AVFCOfficial) December 10, 2024 That would mean they would avoid a play-off round to make it through to the last 16 and Emery says that is the target. “Today was key. Juventus at home, we were thinking more to win but in the end we accepted the draw because it was important for a point to be more or less in the top 24,” he told Amazon Prime. “Today was a match we were thinking at the beginning was key to be a contender to be in the top eight with the last two matches to be played. “It is going to be difficult and we have to get some more points but we now have the possibility to achieve this option. “We are going to enjoy and try to get top eight but we have to be happy because we are in the top 24 and maybe even the top 16. “We weren’t contenders in the beginning to get there but now we have to accept it.” Leipzig, who are flying high near the top of the Bundesliga, are out after losing all six matches. They did pose a threat to Villa, who inflicted some of their own problems on themselves, notably a rare gaffe from goalkeeper Emiliano Martinez for Openda’s equaliser. But Emery was happy with his side’s performance. “I try to enjoy and always we want to improve and sometimes it is hard but today the team were performing well, playing seriously and I was enjoying it,” he added. “We tried to overcome the mistakes we made and we did. More or less we were playing consistently. One mistake and they score but then we played very well. “Champions League is very difficult and we have to expect that every team playing at home are feeling strong. We played with consistency and domination.”White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaignRocket Lab's pioneering suborbital launch last month conducted hypersonic tests for the U.S. military, the company has revealed. The mission in question lifted off on Nov. 24 from the Mid-Atlantic Regional Spaceport (MARS) on Virginia's Wallops Island. It employed HASTE, the suborbital variant of Rocket Lab 's workhorse Electron launcher. Less than 22 hours later, an Electron lofted five "Internet of Things" satellites to orbit for the French company Kinéis, notching an unprecedented spaceflight doubleheader for Rocket Lab. "Mission success. 2 launches in less than 24 hours from 2 pads in 2 different hemispheres," Rocket Lab said via X shortly after the Electron liftoff. Related: Rocket Lab launches 5 IoT satellites on landmark 50th mission (video) For a while, Rocket Lab remained mum about the Nov. 24 mission, which was just the second ever for the HASTE vehicle. But the California-based company broke its silence on Monday (Dec. 9), announcing that the suborbital mission successfully tested "hypersonic technology for the Department of Defense." "This mission provided hypersonic test launch capabilities under the Multi-Service Advanced Capability Hypersonics Test Bed (MACH-TB) project, which aims to increase hypersonic flight testing for the United States in support of technology maturation," Rocket Lab officials said in a statement on Monday . "Rocket Lab’s test platform showcased a new suite of cutting-edge technologies optimized for hypersonic technology tests with vastly increased payloads," the company added. "Rocket Lab also designed, manufactured, assembled and integrated the experimental hypersonic instrumentation which was launched on this mission, but on a highly accelerated timeline." Rocket Lab hit another milestone on its Nov. 25 orbital mission, which it called "Ice AIS Baby:" The launch pushed the total number of satellites deployed by the 59-foot-tall (18 meters) Electron over 200 , to 203. Electron has now flown a total of 54 times, including 13 times so far this year. HASTE's lone mission before the Nov. 24 flight, which Rocket Lab called "HASTE A La Vista," launched in June 2023 , also from the MARS pad.
After departing from Manchester United, Edward Woodward has emerged as a top candidate for the role of sporting director at Arsenal. The news was first reported by ESPN, setting the football world abuzz with speculation and anticipation over the potential appointment.
MongoDB, Inc. to Present at the Barclays 22nd Annual Global Technology Conference
Vikings defense has had a big boost this season from the indefatigable Jonathan Greenard
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen
In conclusion, while the game version of Indiana Jones may be a fun and entertaining way to experience the adventures of the legendary explorer, when it comes to looks and authenticity, the real-life actors portraying the character ultimately come out on top. The charisma, presence, and realism that actors like Harrison Ford bring to the role of Indiana Jones elevate the character to a level that a game character design can only aspire to. Ultimately, in the case of Indiana Jones, real life truly looks better.It all started with a seemingly innocent post on a social media platform, where a netizen jokingly declared, "Out of all the options, I will only drink Diet Coke!" This simple statement quickly snowballed into a full-blown meme, with thousands of users joining in to express their unwavering loyalty to the iconic soda brand. As the chant grew louder and more fervent, it caught the attention of Pepsi, who saw an opportunity to capitalize on the viral sensation.